• Statistically significant improvements are seen for mortality, hospitalization, and cases. 11 studies from 11 independent teams in 6 different countries show statistically significant improvements in isolation (5 for the most serious outcome).
• Meta analysis using the most serious outcome reported shows 38% [19‑52%] improvement. Results are slightly worse for Randomized Controlled Trials and similar for peer-reviewed studies.
• Results are robust — in exclusion sensitivity analysis 9 of 17 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.
• Treatment recommendations are available from Ontario.
• No treatment, vaccine, or intervention is 100% effective and available. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective. Only 12% of fluvoxamine studies show zero events with treatment.
• All data to reproduce this paper and sources are in the appendix. Other meta analyses for fluvoxamine can be found in [Deng, Lee, Lu, Marcec, Nakhaee], showing significant improvements for mortality, hospitalization, and severity.
Percentage improvement with fluvoxamine (more) | Late treatment | Early treatment | All studies | Studies | Patients | Authors |
All studies | 51% [25‑68%]** | 43% [-10‑70%] | 38% [19‑52%]*** | 17 | 36,705 | 414 |
Randomized Controlled TrialsRCTs | 32% [-22‑62%] | 28% [-17‑56%] | 30% [-1‑51%] | 8 | 5,739 | 337 |
Mortality | 51% [22‑69%]** | 65% [-1506‑99%] | 41% [8‑62%]* | 8 | 4,224 | 130 |
HospitalizationHosp. | 22% [-3‑41%] | 37% [-4‑61%] | 25% [6‑40%]* | 10 | 6,384 | 356 |
Cases | - | - | 25% [11‑36%]*** | 2 | 9,116 | 10 |
RCT mortality | 30% [-26‑63%] | -200% [-7253‑88%] | 27% [-33‑60%] | 2 | 2,973 | 62 |
Covid Analysis et al., Jun 2023, preprint, 1 author.